Brokerages Expect BioSpecifics Technologies Corp. (BSTC) to Post $0.72 Earnings Per Share

Shares of BioSpecifics Technologies Corp. (NASDAQ:BSTC) have received a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.

Analysts have set a 12 month consensus price target of $85.00 for the company and are anticipating that the company will post $0.72 EPS for the current quarter, according to Zacks. Zacks has also given BioSpecifics Technologies an industry rank of 69 out of 256 based on the ratings given to related companies.

BSTC has been the topic of several analyst reports. Zacks Investment Research cut BioSpecifics Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, January 29th. HC Wainwright reiterated a “buy” rating and set a $81.00 price target on shares of BioSpecifics Technologies in a research report on Friday, January 25th. Finally, BidaskClub cut BioSpecifics Technologies from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 24th.

In other news, Director Paul Gitman sold 5,000 shares of the business’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $65.83, for a total transaction of $329,150.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 21.40% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of BSTC. Advantage Investment Management LLC purchased a new position in shares of BioSpecifics Technologies during the first quarter worth about $42,000. Great West Life Assurance Co. Can purchased a new position in shares of BioSpecifics Technologies during the fourth quarter worth about $54,000. Legal & General Group Plc grew its holdings in shares of BioSpecifics Technologies by 50.1% during the fourth quarter. Legal & General Group Plc now owns 1,211 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 404 shares in the last quarter. BNP Paribas Arbitrage SA grew its holdings in shares of BioSpecifics Technologies by 60,150.0% during the first quarter. BNP Paribas Arbitrage SA now owns 1,205 shares of the biopharmaceutical company’s stock worth $75,000 after purchasing an additional 1,203 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY grew its holdings in shares of BioSpecifics Technologies by 356.5% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 2,100 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 1,640 shares in the last quarter. 60.69% of the stock is owned by institutional investors.

Shares of BSTC traded down $1.67 during midday trading on Thursday, hitting $64.33. 104,590 shares of the company traded hands, compared to its average volume of 60,435. BioSpecifics Technologies has a one year low of $40.58 and a one year high of $73.31. The stock has a market cap of $468.20 million, a PE ratio of 23.56 and a beta of 1.27.

BioSpecifics Technologies (NASDAQ:BSTC) last announced its quarterly earnings results on Friday, May 10th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.62 by ($0.02). BioSpecifics Technologies had a net margin of 59.99% and a return on equity of 21.08%. The company had revenue of $8.13 million for the quarter, compared to the consensus estimate of $8.10 million. Equities analysts expect that BioSpecifics Technologies will post 3 earnings per share for the current year.

BioSpecifics Technologies Company Profile

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brands.

Featured Article: What is the LIBOR?

Get a free copy of the Zacks research report on BioSpecifics Technologies (BSTC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.